ABSTRACT
Introduction: In patients with coronavirus disease 2019 (COVID-19), the prevalence of hyponatremia has been reported with varying outcomes. Objective(s): The aim of this study was to evaluate the prevalence of hyponatremia in hospitalized patients with COVID-19. Patients and Methods: In this multicenter cross-sectional study, information about hospitalized patients with COVID-19 admitted between March 2020 and September 2020, including age, gender, and serum levels of sodium, creatinine, and potassium, as well as blood urea nitrogen (BUN), was analyzed, while P value level less than 0.05 was considered significant. Result(s): A total of 667 hospitalized patients with COVID-19 were enrolled in the study, of which 54.4% were male. The median age of patients was 63 years old. About 39.4% of patients had hyponatremia on admission day. More than 80% of patients had mild hyponatremia. The median age of the hyponatremia group was significantly higher than that of eunatremia group. Conclusion(s): Our data showed that hyponatremia is observed in hospitalized patients with COVID-19 and is often mild.Copyright © 2023 The Author(s);Published by Society of Diabetic Nephropathy Prevention.
ABSTRACT
Hemoperfusion is an effective modality in removing certain toxins from the blood, especially those that bind to proteins in the body. Hemoperfusion has shown a therapeutic effect on COVID-19 patients. In this case series, we report four patients without effective results following the use of hemoperfusion on the recovery of COVID-19 patients. This study is a case series which carried out on four patients referred to COVID-19 ward of Velayat hospital in Qazvin, Iran. The mean age of the COVID-19 patients was 52.75 +/- 18 years. The mean stay at the hospital was 21.5 +/- 15.15 days. This study showed that hemoperfusion cannot show a significant therapeutic effect on COVID-19.